Rubio-Guerra AF, Medina-Santillán R, Morales-López H, Lozano-Nuevo JJ, Domínguez-Nariniain RS, Vargas-Ayala G

Language: Spanish
References: 16
Page: 357-362
PDF size: 472.25 Kb.

ABSTRACT

Background: Ankle-braquial index (ABI) is an useful tool for the diagnosis of peripheral arterial disease, but it is also an independent and positive predictor of endothelial dysfunction and cardiovascular risk. In the INDAGA study, 76% of the patients with an ABI ‹ 0.9 were hypertensive. Inhibitors of the renin angiotensin system ameliorate vascular function and must improve the ABI.
Objective: To study if the management of arterial hypertension with inhibitors of the angiotensin converting enzyme (ACEI) improves the ABI.
Material and method: A study in which 30 hypertensive patients never treated with ACEI nor with antagonist of the angiotensin receptor were evaluated. Patients were treated with moexipril 7.5 mg/day, the dose was titrated to 15 mg if blood pressure values ‹140/90 mmHg were not reached. In all patients the ABI was registered with a 5 megahertz doppler (Summit doppler L250, Life Dop., USA) at the beginning and the end of the study 3 months later, an ABI between 0.9 and 1.3 was considered normal. Statistical analysis was performed with the Wilcoxon test.
Results: In all patients a good control of blood pressure values was obtained (166/96 to 129/77 mmHg, p‹ 0.01), although 15 patients required increasing the dose. The ABI was modified from 0.93 to 1.03 (p‹0.01), in 11 patients the management normalized the ABI above 0.9. A regression analysis showed that the improvement in the ABI was independent of the blood pressure control.
Conclusion: Treating hypertension with moexipril ameliorates the ABI in hypertensive patients independently from its antihypertensive effect and explains the effect of ACEI in the improvement of cardiovascular prognosis.

REFERENCES

1. Núñez Armendáriz M. Hipertensión en la mujer postmenopáusica. Sx Cardiometabólico Diabetes 2014;1:87-92.

2. Cantú-Brito C, Chiquete E, Duarte-Vega M, Rubio-Guerra A y col. Estudio multicéntrico INDAGA. Índice tobillo-brazo anormal en población mexicana con riesgo vascular. Rev Med IMSS 2011;45:239-246.

3. Rubio-Guerra AF. Foro Clínico: hipertensión en pacientes con enfermedad arterial periférica. Rev Invest Clin 2013;65:263-268.

4. Task Force for the management of arterial hypertension of the European Society of Hypertension; Task Force for the management of arterial hypertension of the European Society of Cardiology. 2013 ESH/ESC Guidelines for the Management of Arterial Hypertension. Blood Press 2013;22:193-278.

5. Madamanchi NR, Vendrov A, Runge MS. Oxidative stress and vascular disease. Arterioscler Thromb Vasc Biol 2005;25:29-38.

6. Rubio-Guerra AF, Duran-Salgado MB. Antihypertensive treatment and vascular extracellular matrix remodeling. Cardiology 2014;127:245-246.

7. Dupuis F, Vincent JM, Limiñana P, Chillon JM, et al. Effects of suboptimal doses of the AT1 receptor blocker, telmisartan, with the angiotensin-converting enzyme inhibitor, ramipril, on cerebral arterioles in spontaneously hypertensive rat. J Hypertens 2010;28:1566-1573.

8. Coppola G, Romano G, Corrado E, Grisanti RM, Novo S. Peripheral artery disease: potential role of ACE-inhibitor therapy. Vasc Health Risk Manag 2008;4:1179-1187.

9. Chrysant SG, Chrysant GS. Pharmachological and clinical profile of moexipril. A Concise Review. J Clin Pharmacol 2004;44:827-836.

10. Kum F, Karalliedde J. Critical appraisal of the differential effects of antihypertensive agents on arterial stiffness. Integr Blood Press Control 2010;3:63-71.

11. Shahin Y, Barnes R, Barakat H, Chetter IC. Meta-analysis of angiotensin converting enzyme inhibitors effect on walking ability and ankle brachial pressure index in patients with intermittent claudication. Atherosclerosis 2013;231:283-290.

12. Ahimastos AA, Lawler A, Reid CM, Blombery PA, Kingwell BA. Ramipril markedly improves walking ability in patients with peripheral arterial disease: a randomized trial. Ann Intern Med 2006;144:660-664.

13. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FGR on behalf of the TASC II Working Group. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). Eur J Vasc Endovasc Surg 2007;33:S1-S75.

14. Rubio-Guerra AF, Durán-Salgado MB. Insulina, sistema renina-angiotensina-aldosterona y disfunción endotelial. Rev Med IMSS 2011;49:581-584.

15. Rubio-Guerra AF. El mexicano hipertenso. Sx Cardiometabólico Diabetes 2014;1:125-126.

16. Giugliano G, Sannino A, Brevetti L, Perrino C, et al. Ankle/brachial index to everyone. BMC Surg 2012;12(Suppl 1):S18-S21.